Arnoud J Templeton
Arnoud J Templeton
St. Claraspital Basel, Switzerland
Verified email at unibas.ch
Title
Cited by
Cited by
Year
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ...
JNCI: Journal of the National Cancer Institute 106 (6), 2014
13072014
Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis
AJ Templeton, O Ace, MG McNamara, M Al-Mubarak, FE Vera-Badillo, ...
Cancer Epidemiology and Prevention Biomarkers 23 (7), 1204-1212, 2014
3522014
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2014
2532014
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum, AJ Templeton, ...
Lung cancer 111, 176-181, 2017
1962017
Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
JL Ethier, D Desautels, A Templeton, PS Shah, E Amir
Breast Cancer Research 19 (1), 1-13, 2017
1692017
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
I Cima, R Schiess, P Wild, M Kaelin, P Schüffler, V Lange, P Picotti, ...
Proceedings of the National Academy of Sciences 108 (8), 3342-3347, 2011
1692011
HER3 overexpression and survival in solid tumors: a meta-analysis
A Ocana, F Vera-Badillo, B Seruga, A Templeton, A Pandiella, E Amir
JNCI: Journal of the National Cancer Institute 105 (4), 266-273, 2013
1612013
Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of …
D Lorente, J Mateo, AJ Templeton, Z Zafeiriou, D Bianchini, ...
Annals of Oncology 26 (4), 750-755, 2015
1302015
Systemic therapy for non–clear cell renal cell carcinomas: A systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ...
European urology 67 (4), 740-749, 2015
1212015
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis
A Ocana, F Vera-Badillo, M Al-Mubarak, AJ Templeton, ...
PloS one 9 (4), e95219, 2014
1212014
Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio
AJ Templeton, C Pezaro, A Omlin, MG McNamara, R Leibowitz‐Amit, ...
Cancer 120 (21), 3346-3352, 2014
1182014
Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic
GS Kulkarni, T Hermanns, Y Wei, B Bhindi, R Satkunasivam, ...
Journal of Clinical Oncology 35 (20), 2299-2305, 2017
1132017
Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy
AJ Templeton, JJ Knox, X Lin, R Simantov, W Xie, N Lawrence, R Broom, ...
European urology 70 (2), 358-364, 2016
1102016
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
AJ Templeton, V Dutoit, R Cathomas, C Rothermundt, D Bärtschi, ...
European urology 64 (1), 150-158, 2013
1082013
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of …
AJ Templeton, FE Vera-Badillo, L Wang, M Attalla, P De Gouveia, ...
Annals of oncology 24 (12), 2972-2977, 2013
1062013
Neutrophils in cancer: prognostic role and therapeutic strategies
A Ocana, C Nieto-Jiménez, A Pandiella, AJ Templeton
Molecular cancer 16 (1), 137, 2017
992017
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two …
RJ Van Soest, AJ Templeton, FE Vera-Badillo, F Mercier, G Sonpavde, ...
Annals of Oncology 26 (4), 743-749, 2015
962015
Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder
T Hermanns, B Bhindi, Y Wei, J Yu, AP Noon, PO Richard, JR Bhatt, ...
British journal of cancer 111 (3), 444-451, 2014
952014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
R Leibowitz-Amit, AJ Templeton, A Omlin, C Pezaro, EG Atenafu, ...
Annals of oncology 25 (3), 657-662, 2014
862014
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)
C Rothermundt, S Hayoz, AJ Templeton, R Winterhalder, RT Strebel, ...
European urology 66 (3), 468-474, 2014
812014
The system can't perform the operation now. Try again later.
Articles 1–20